118th Congress · HOUSE BILLBILL

H.R. 1375 — EFFECTIVE Act

“To allow the Secretary of Health and Human Services to deny approval of a new drug application for an opioid analgesic drug on the basis of such drug not being clinically superior to other commercially available drugs.”

Health

Introduced Mar 3, 2023

Last action Mar 10, 2023

Pipeline · Bill → Law

Step 1

Introduced

Mar 3, 2023

Step 2

Referred

Mar 10, 2023

E&C

Step 3

Committee

Step 4

House floor

Step 5

Senate

Step 6

Resolve Changes

Step 7

Signed

SummaryCRS Summary

This bill specifies that the Food and Drug Administration may deny an application for a new opioid analgesic drug (i.e., opioid medication) upon a determination that the drug does not provide a significant advantage with respect to safety or effectiveness as compared to other drugs.

Provisions · 2 sectionsIntroduced in House

Timeline · 3 actions

Mar 10, 2023

Referred to the Subcommittee on Health.

Mar 3, 2023

Introduced in House

Mar 3, 2023

Referred to the House Committee on Energy and Commerce.